ATG-F
ApprovedCompleted 2 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
De Novo Kidney Transplant Patients
Conditions
De Novo Kidney Transplant Patients
Trial Timeline
Jul 31, 2012 → Dec 31, 2015
NCT ID
NCT02267512About ATG-F
ATG-F is a approved stage product being developed by Astellas Pharma for De Novo Kidney Transplant Patients. The current trial status is completed. This product is registered under clinical trial identifier NCT02267512. Target conditions include De Novo Kidney Transplant Patients.
What happened to similar drugs?
8 of 15 similar drugs in De Novo Kidney Transplant Patients were approved
Approved (8) Terminated (1) Active (6)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02267512 | Approved | Completed |
Competing Products
19 competing products in De Novo Kidney Transplant Patients